China Biopharma has reached an agreement of understanding with a biopharmaceutical firm in China to expand its product line from human vaccines to intravenous therapies for the treatment of autoimmune diseases.

China Biopharma plans to market Intravenous Immunoglobulin on the international market beginning in the second quarter of 2007. IVIG is a solution containing blood components, specifically immunoglobulins that help regulate the immune system. IVIG is used to treat a host of life-threatening and serious autoimmune diseases, including Chronic Inflammatory Demyelinating Polyneuropathy, a form of nerve disease or peripheral neuropathy. IVIG and its components represent a multi-billion dollar market.

Peter Wang, CEO of China Biopharma, Inc., states, "We will continue to develop and distribute vaccines in China, while we diversify our product line into biological treatments that target several of today's most prevalent diseases. IVIG has emerged as an important therapy for various neurological diseases and is also a life-saving treatment for patients with autoimmune diseases. Due to its limited supply outside the U.S., availability of IVIG is still inadequate in a number of countries. As a result, the price for IVIG has increased dramatically in the last few years, creating a very promising new market opportunity for China Biopharma."

Through its operating subsidiaries, the company develops and distributes human vaccine products throughout China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma says it is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe.